Name: Latest research reports of Cipla Ltd. authored by Asit C Mehta Investment Interrmediates and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 4
Author: Asit C Mehta Investment Interrmediates

Cipla Ltd.

NSE: CIPLA | BSE: 500087 | ISIN: INE059A01026 | Industry: Pharmaceuticals
| Mid-range Performer

1528.2000 17.10 (1.13%)

NSE Apr 22, 2025 15:31 PM

Volume: 955.0K

Cipla Ltd.

17 Jan 2025

1528.20

1.13%

Empowering health, Enriching Lives

Accumulate: Cipla Ltd.

Asit C Mehta Investment Interrmediates

Cipla's "Future Fit" strategy outlines ambitious growth objectives, including becoming India’s 2nd largest pharmaceutical company, leading South Africa’s prescription and OTC markets, ranking 2nd in U.S. respiratory generics, and doubling international revenue.

Cipla Ltd. has an average target of 1707.30 from 11 brokers.